Found 385 results
Kasturi SPai, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL et al..  2017.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.. J Virol. 91(4)
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med.
Lee J H, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, Kong L, Wu NC, McBride R, Sok D, Pauthner M et al..  2017.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.. Immunity. 46(4):690-702.
Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH et al..  2017.  BST-2 Expression Modulates Small CD4 Mimetic Sensitization of HIV-1-infected cells to ADCC.. J Virol.
Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Wiesch JSchulze Zu, Cubas R, Porichis F, Shalek AK et al..  2017.  Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.. JCI Insight. 2(2):e89574.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)
Antunes Rda Silva, Paul S, Sidney J, Weiskopf D, Dan JM, Phillips E, Mallal S, Crotty S, Sette A, Arlehamn CSLindesta.  2017.  Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses.. PLoS One. 12(1):e0169086.
Haynes BF, Burton DR.  2017.  Developing an HIV vaccine.. Science. 355(6330):1129-1130.
Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ et al..  2017.  Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.. MBio. 8(1)
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature.
Struwe WB, Stuckmann A, Behrens A-J, Pagel K, Crispin M.  2017.  Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.. ACS Chem Biol. 12(2):357-361.
Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park S-KRobin, Sok D, Su CYao, Delahunty CM, Menis S et al..  2017.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.. Nat Commun. 8:14954.
Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RT.  2017.  Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.. Immunity. 46(5):792-803.e3.
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD et al..  2017.  HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection.. J Virol. 91(7)
Ward AB, Wilson IA.  2017.  The HIV-1 envelope glycoprotein structure: nailing down a moving target.. Immunol Rev. 275(1):21-32.
McCoy LE, Burton DR.  2017.  Identification and specificity of broadly neutralizing antibodies against HIV.. Immunol Rev. 275(1):11-20.
Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T et al..  2017.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.. J Virol. 91(7)
Irimia A, Serra AM, Sarkar A, Jacak R, Kalyuzhniy O, Sok D, Saye-Francisco KL, Schiffner T, Tingle R, Kubitz M et al..  2017.  Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.. PLoS Pathog. 13(2):e1006212.
Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M.  2017.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)
Escolano A, Dosenovic P, Nussenzweig MC.  2017.  Progress toward active or passive HIV-1 vaccination.. J Exp Med. 214(1):3-16.
Barouch DH, Thomas SJ, Michael NL.  2017.  Prospects for a Zika Virus Vaccine.. Immunity. 46(2):176-182.
Behrens A-J, Crispin M.  2017.  Structural principles controlling HIV envelope glycosylation.. Curr Opin Struct Biol. 44:125-133.
Wibmer CKurt, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, M Joyce G, Ndabambi N et al..  2017.  Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.. PLoS Pathog. 13(1):e1006074.
Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V et al..  2017.  T cells control the generation of nanomolar-affinity anti-glycan antibodies.. J Clin Invest.
Havenar-Daughton C, Lee J H, Crotty S.  2017.  Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.. Immunol Rev. 275(1):49-61.